The global surge in demand for GLP-1 receptor agonists has exposed severe bottlenecks in specialized pharmaceutical packaging and sterile fill-finish operations. Contract manufacturing organizations (CMOs) are committing billions in capital expenditure to bridge the gap.
Capacity Constraints
Shortages of autoinjector devices remain the primary constraint in the GLP-1 distribution chain. Medical device suppliers are scaling injection molding facilities to expand monthly output.
Economic Ripple Effects
Healthcare payers are introducing stricter prior-authorization criteria to manage budget impacts. Simultaneously, retail pharmacy chains report shifts in patient foot traffic and companion medication fulfillment.